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Summary We measured immunoreactive EGF and TGFa in prostate tissue extracts obtained from 19
patients with benign prostatic hyperplasia (BPH) and 19 with cancer of the prostate (CaP). Whilst both BPH
and CaP expressed EGF (BPH =195.61 ± 19.94 ng g' protein; CaP = 235.60 ± 24.45 ng g' protein) and
TGFa (BPH = 92.57 ± 7.60 ngg' protein; CaP = 100.73 ± 15.47 ng g-' protein) in equal concentrations, the
levels of EGF in any tissue extract were on average twice those of TGFa. Furthermore analysis of the
individual growth factor data revealed a direct correlation between EGF and TGFa in both BPH (r = 0.72,
P<0.001) and CaP (r = 0.69, P<0.001). When the tumours were classified according to their Gleason score, a
slight but significant increase in growth factor concentrations was noted as the tumour became less
differentiated. We also measured the concentrations of testosterone and dihydrotestosterone (DHT) in prostate
extracts with a view of elucidating the relationship between androgen and growth factors in this gland. There
was a small positive correlation only between testosterone and EGF (r = 0.62, P<0.05) and testosterone and
TGFa (r = 0.61, P<0.05) in CaP. The absence of any similar correlation in BPH where DHT becomes the
predominant hormone may suggest an indirect role for testosterone in the regulation of growth factor
production.
Since the realisation that androgens are not alone in
influencing the growth and regulation of the prostate, several
investigations into the role of growth factors and their rela-
tionship with androgens have been undertaken. Initially,
studies on the normal rat prostate demonstrated that the
receptors for epidermal growth factor (EGF) were down
regulated by androgens (Traish & Wotiz, 1987; St. Arnaud et
al., 1988). Subsequently experiments on androgen responsive
prostate cancer cell lines revealed relatively low numbers of
EGF receptors whilst androgen unresponsive cells expressed
higher EGF receptor numbers (MacDonald & Habib, 1992).
The correlation between EGF receptor expression and endoc-
rine status suggest that steroid hormones might influence the
response to growth factors, by altering growth factor recep-
tor expression, but this response may also reflect the species
from which the prostate cells were derived. Receptors for
EGF have also been identified in human benign hyperplastic
prostate (BPH) but their concentrations were markedly
depleted in the poorly differentiated prostate cancer (Maddy
et al., 1989). Significantly, this loss in EGF-receptor expres-
sion is manifested at a time when the prostate tumour
exhibits a reduced sensitivity to steroid hormones. It is not
clear whether these two events are interrelated but the pro-
gression to an androgen independent state may, in part, be
due to a reduced need for exogenous mitogens because of the
the autologous production of growth factors (Sporn &
Roberts, 1985). Transforming growth factor alpha (TGFa) is
a polypeptide growth factor which has been reported to
modulate autocrine growth in several tumour systems (Bates
et al., 1986; Hofer et al., 1991; Lloyd et al., 1992; Mac-
Donald et al., 1990) but no one has so far related the
presence of this growth factor in BPH and cancer of the
prostate to the tissular concentrations of EGF and prostate
androgens. The purpose of this study is to investigate some
of these relationships.
Materials and methods
Prostate tissue
Prostate tissue was obtained at the time of transurethral
resection from 19 patients with BPH and 19 patients with
prostatic cancer. The tissue was transported immediately to
the laboratory chopped into 1-3 g pieces washed in
2 x 150 mM sodium chloride solution and dry blotted.
Several sections from each specimen were sent for his-
tological examination and grading of the cancerous tissue by
the Gleason system (Gleason, 1977). The remainder of the
tissue was snap frozen in liquid nitrogen and finally
pulverised in a micro-dismembrator (Braun AG, Melsungen,
Germany). The powdered tissue was then lyophilised to
dryness and stored at - 70°C until needed. For growth factor
studies 70 mg of the lyophilised material was used whereas
only 50 mg were required for steroid measurements.
Extraction ofgrowthfactors
Lyophilised samples were resuspended in 1 ml buffer
(50 mmol 1 Tris, 5 mol 1' of phenyl-methylsulphonyl
fluoride, 2 mmol I1' of EDTA pH7.4) containing 1,000
counts of either '251I-EGF or '25I-TGFx to monitor
manipulative losses. The samples were homogenised with a
glass/glass Dounce Homogeniser and left on ice for 1 h to
equilibrate. The homogenates were then centrifuged, the
supernatants saved and the resultant pellets were resuspended
in 2 ml of enzyme mixture (230 Uml-' of collagenase,
125 Uml-' of hyaluronidase in 150 mmol 1' of NaCI) and
incubated overnight at 37C; these conditions were found to
be optimal and ensured maximum growth factor recovery.
The digested pellets were subsequently sonicated (six cycles of
20s with 1 min cooling interval at an amplitude of 22 ,;
MSE soniprep 150) the resultant mixture was centrifuged as
before, the supernatant saved and the pellet was resuspended
in 2 ml Tris buffer. Homogenisation, centrifugation and
resuspension were then repeated twice with the supernatants
always being saved. The supernatants were then pooled and
the recoveries were assessed. The mean recovery of '251I-EGF
added at the beginning of the extraction procedure was
72 ± 6% whilst that of 125I-TGFo was 69 ± 8%. The. super-
natants were finally snap frozen, lyophilised to dryness and
stored at - 700 until required.
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Radio-immunoassaysfor hEGF and hTGFc
The concentrations of immunoreactive hEGF and hTGFa in
the lyophilised samples were determined by a liquid phase
competitive RIA. Briefly, the lyophilised material was recons-
tituted in 7001l of PBS (0.02 mol 1- of Na2HPO4.2H20,
0.02 mol 1-' Na2HPO4.2H20, 0.9% NaCl, 3.7 g 1-' of
EDTA, I g l- of BSA, pH7.4) and the assays were per-
formed in triplicate employing 100 gil of the reconstituted
lyophilised material. The radio immunoassay for hEGF was
as described previously (MacDonald et al., 1990). No cross
reaction was found with transforming growth factor-a, which
exerts all of its biological effects via the EGF receptor, up to
concentrations of 1 fgml-'. Cross reactivity of this antiserum
with a large variety of other substances has been tested by
other investigators (Gregory et al., 1979; Jaspar et al., 1985).
TGFa content was analysed using a commercial kit (Penin-
sula Laboratory Europe Ltd, St Helens, Merseyside) with
rTGF1 as radioiodinated tracer and hTGFa as reference
standard. Antisera to the rTGF1 was raised in rabbits and
purchased from Peninsula Laboratory Europe Ltd. The rab-
bit anti-rat TGF1 antisera recognises both mouse and
hTGFa but does not crossreact with either mouse or hEGF.
Half maximal inhibition of binding of the 1251I-peptide to the
antibody occurred at 140pg/tube.
Measurement ofandrogens
Specific radioimmunoassays for testosterone and dihydrotes-
tosterone (DHT) were carried out after a single separation on
Gelman ITLC plates using an antiserum against dihydrotes-
tosterone (Guildhay Antisera Ltd, Guildford, Surrey). The
extraction of the androgens from the tissue, chromatographic
separation, radioimmunoassay and reliability of the method
have already been described in detail (Habib et al., 1976;
Houston et al., 1985). Briefly 50 mg of the lyophilised
powdered tissue extract was reconstituted in 2 ml of Tris HCI
buffer containing 1,000 cpm radioactive steroids for each of
the androgens to be assayed for recovery. Following equilib-
ration, the steroids were extracted three times with
diethylether and the pooled extracts were dried down, recons-
tituted in 50 gIl ethanol and separated on thin layer
chromatography plates. The steroids were subsequently ext-
racted, reconstituted in PBS buffer, recovery was assessed
and the radioimmunoassay carried out.
Protein determination
Protein was estimated by the method of Bradford (1976)
using bovine serum albumin as standard.
Data analysis
All analysis were performed in triplicate and the data has
been presented as mean ± standard error of the mean.
Differences in growth factors and androgen concentrations
were tested for statistical significance by student t-test. Cor-
relation of the degree of association for any two parameters
was determined by calculation of the correlation co-efficient
(r): r values presenting a probability of <0.05 were con-
sidered to be statistically significant.
Results
Figure 1 demonstrates the relative concentrations of EGF
and TGFx in tissue extracts obtained from patients with
BPH (n = 19) and prostate cancer (n = 19). The
mean ± s.e.m. values (ngg-' protein) for EGF
(195.61 ± 19.94) and TGFa (92.57 ± 7.60) in the BPH speci-
mens were slightly but not significantly (P>0.3) lower than
those measured in the cancer tissue extracts
(EGF = 235.60 ± 24.45; TGFa = 100.73 ± 15.47).
Additionally the EGF/TGFa ratios in both tissue types
were found to be of the same order of magnitude (mean
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Figure 1 Comparison of immunoreactive EGF and TGFa in
tissue extracts obtained from 19 patients with BPH and 19
patients with cancer of the prostate (CaP). The bars represent the
mean values of all extracts within each group ± s.e.m.
value for BPH = 2.12; CaP = 2.34) with the EGF concentra-
tion in each tissue extract being approximately twice the
TGFa concentration.
Analysis of the individual EGF and TGFa values in BPH
and CaP by-linear regression (Figures 2 and 3) resulted in a
direct correlation between EGF and TGFx in both BPH
(r = 0.72, P<0.001) and CaP (r = 0.69, P<0.001).
Furthermore when 13 of the tumours were classified ac-
cording to their histological grade (Gleason score: primary-
+ secondary pattern) and these were in turn correlated to
their growth factor concentrations, a significant correlation
was found between the Gleason score and EGF (r = 0.65,
P<0.02) and the Gleason score and TGFa (r = 0.57,
P<0.05) with the concentration of the growth factors in the
tissue extracts increasing as the tumour becomes less
differentiated (Table I).
Testosterone and DHT concentrations were also measured
in the tissue extracts. These measurements confirmed our
earlier findings revealing significantly higher levels of tes-
tosterone in CaP (289.26 ± 76.9, n = 12) when compared to
BPH (94.02 ± 14.4, n = 19) whilst DHT concentrations were
significantly higher in BPH (201.64 ± 38.4) than in CaP tissue
extracts (79.11 ± 27.8). The differences between the two
groups were statistically significant (P<0.01).
Attempts to correlate the steroid hormone levels with the
growth factor concentrations employing linear regression
Table I Effect of tumour differentiation on tissue EGF and TGFo
concentrations
Gleason score EGF TGFt
(ngg-' protein) (ngg-' protein)
2-4 135.08a (1) 32.24 (1)
5-7 203.78±24.08b (8) 91.62± 12.95 (8)
8-10 359.18± 54.06 (4) 123.38±41.6 (4)_
aParentheses denote number of tumours in each group. bMean±
s.e.m.
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Figure 2 Relationship between the concentration of
immunoreactive EGF and that of immunoreactive TGFa in pros-
tate tissue extracts from 19 patients with benign prostatic hyperp-
lasia (r= 0.72, P<0.001).
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Figure 3 Relationship between the concentrations of
immunoreactive EGF and TGFa in the tissue extracts obtained
from 19 patients with carcinoma of the prostate (r = 0.69,
P<0.001).
yielded positive correlation only between testosterone and
EGF (r = 0.62, P<0.05) and testosterone and TGFa
(r = 0.61, P<0.05) in CaP (Figure 4). No similar correlation
was found in BPH or indeed between DHT and the growth
factors for both tissue extracts.
Discussion
The present study confirms the presence of immunoreactive
EGF and TGFa in tissue extracts from hyperplastic and
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prostate. Regression lines are shown with correlation coefficients
(r).
neoplastic human prostates. These findings are consistent
with the reports on the production of EGF-related peptides
in human prostate tissue (Gregory et al., 1987; Fowler et al.,
1986) and TGFa-like molecules by prostate cancer cell lines
(Connolly & Rose, 1989; MacDonald et al., 1990; Hofer et
al., 1991). TGFax was originally characterised by its ability to
induce phenotypic transformation of normal cells (Sporn &
Roberts, 1985) and the elevated expression of this growth
factor in transformed cells has been reported (Marquardt et
al., 1983). However, TGFa has since been found also in a
variety of other normal as well as neoplastic tissues (Coffey
et al., 1987; Gomella et al., 1989; Lloyd et al., 1992), sugges-
ting a possible role for this growth factor in normal cell
physiology.
The expression of TGFx in human benign prostate tissue
has not previously been reported. In the current study, the
TGFa concentrations in BPH were compatible with those
measured in other tissues (Liu et al., 1990). It was also of
interest to note that there was no difference in the TGFa
levels between BPH and prostate cancers even though there
was a marginal increase in TGFo expression as the tumour
became less differentiated. Significantly however, this increase
in TGFa concentrations was manifested at a time when the
expression of the EGF-receptor is down regulated (Maddy et
al., 1989) thus raising further the possibility that TGFa may
be excerting its biological effects by interacting with receptor
sites other than those associated with EGF (Winkler et al.,
1989). Although one should not exclude the possibility that
higher levels of EGF-R activation can also result in more
rapid receptor turnover and/or down regulation of receptor
expression.
Until recently TGFa was thought to be the counterpart of
EGF in cancer, produced by the neoplastic prostate cell at
the expense of EGF as part of an autocrine regulatory
mechanism to reduce the need of these cells for exogenous
mitogens (MacDonald et al., 1990; Hofer et al., 1991). How-
ever the presence of immunoreactive EGF in extracts from
BPH and cancer at equivalent concentrations highlights, once
more, the complexity of the biological actions of these two
growth factors in the human prostate. Additionally, the close
association found between TGFx and EGF in the two tissue
types suggests that the mechanism responsible for the secre-
tion of one of these growth factors may also be responsible
for controlling the production of the other. Whether both
growth factors act in synergy to induce neoplastic transfor-
mation in the human prostate still remains to be clarified. In
view of the increasing interest in the role of growth factors in
endocrine related tumours (Bates et al., 1986; Lai et al., 1989;
MacDonald & Habib, 1992; Perheentupa et al., 1984)
attempts were also made to establish the relationship between
steroid hormone concentrations and the growth factors in the
prostate extracts. Whilst there was some correlation between
testosterone and TGFa and EGF in prostate cancer, the
absence of a parallel association in BPH where DHT is the
active steroid may possibly suggest an indirect role for tes-
tosterone in the regulation of prostatic EGF and TGF&c.
Though this relationship will need to be confirmed in a more
dynamic system, the production of growth factors in some
tissues has been shown to be sensitive to sex hormones. This
has been witnessed in a number of systems including the
submaxillary gland where testosterone increases EGF levels
(Perheentupa et al., 1984), in various human cancer cell lines
where oestradiol influences the production of EGF related
polypeptides (Lippman et al., 1986) and in breast cyst fluid
where androgens modulate EGF concentrations (Lai et al.,
1989).
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